These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36313668)

  • 1. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NSM; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():1028118. PubMed ID: 36313668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():883399. PubMed ID: 35847924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
    Wu C; Zhang J; Wu X
    Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
    Liu B; Kou Y
    J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
    Symcox M; Somaiah N
    Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
    Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
    Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
    Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
    Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
    Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
    Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.
    Liao W; Xu H; Hutton D; Wu Q; Zhou K; Luo H; Lei W; Feng M; Yang Y; Wen F; Li Q
    Front Oncol; 2021; 11():692005. PubMed ID: 34938653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report.
    Huang S; Guo X; Xia Y; Ding L; Zhai E; Chen S; He Y; Cai S; Zhang X
    Ann Transl Med; 2022 Jan; 10(2):118. PubMed ID: 35282043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Comparison of prognosis between microscopically positive and negative surgical margins for primary gastrointestinal stromal tumors: A systematic review and meta-analysis.
    Liu Z; Zhang Y; Yin H; Geng X; Li S; Zhao J; Zeng Z; Ye X; Yu J; Feng F; Kang W
    Front Oncol; 2022; 12():1110168. PubMed ID: 36761432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 18. Testing Ripretinib against Sunitinib in GIST.
    Cancer Discov; 2022 Mar; 12(3):591-592. PubMed ID: 35086925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
    Senchak J; Ahr K; von Mehren M
    Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.